Does Vitamin D Improve Glycemic Control in Type II DM? (no)
This study is currently recruiting participants.
Verified December 2011 by King Faisal Specialist Hospital & Research Center
Sponsor:
King Faisal Specialist Hospital & Research Center
Information provided by (Responsible Party):
Muhammad Maher Hammami, King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT01170442
First received: July 25, 2010
Last updated: December 11, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Vitamin D status has been negatively associated with the presence of type II DM and glycemic control. However, a cause-effect relationship between vitamin D deficiency and glycemic control has not been established. The investigators plan to conduct a double blind, randomized, placebo controlled trial on the effect of vitamin D supplementation on glycemic control in Type II DM.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus Vitamin D Deficiency |
Drug: vitamin D3 2000 IU Drug: vitamin D3 5000 IU Drug: Placebo |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
Official Title: | Does Vitamin D Improve Glycemic Control in Type II DM? A Double Blind Randomized Controlled Trial |
Resource links provided by NLM:
Genetics Home Reference related topics:
6q24-related transient neonatal diabetes mellitus
carbamoyl phosphate synthetase I deficiency
Drug Information available for:
Cholecalciferol
U.S. FDA Resources
Further study details as provided by King Faisal Specialist Hospital & Research Center:
Primary Outcome Measures:
- Area under the curve of HA1C. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Area under the curve for BP [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- area under the curve of weight [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- area under the curve for 25 OH vitamin D level [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- area under the curve of fasting blood glucose [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- area under the curve of 2 hour post breakfast glucose [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- fasting insulin to glucose ratio [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- incidence of hypercalcemia [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- incidence of hypercalciuria [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Estimated Enrollment: | 300 |
Study Start Date: | December 2011 |
Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: vitamin D3 2000 IU |
Drug: vitamin D3 2000 IU
vitamin D3 2000 IU orally, daily for 6 months
Other Name: cholecalciferol
|
Experimental: vitamin D3 5000 IU |
Drug: vitamin D3 5000 IU
vitamin D3 5000 IU orally, daily for 6 months
Other Name: cholecalciferol
|
Placebo Comparator: Placebo |
Drug: Placebo
placebo orally, daily for six months
Other Name: Placebo
|
Eligibility
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Type II diabetics living in Riyadh area who consume no more than one serving of milk/day
- Do not take vitamin supplement
- Habitually have less than 10 hour of sun exposure per week
- Don't suffer from granulomatous conditions, liver disease, or kidney disease
- Don't take anticonvulsants, barbiturates, or steroids.
- Stable glycemic control (not more than 0.5% difference between current HA1c and a HA1c obtained 2-4 months earlier)
- Current HA1c between 6.5 and 8%, and current total 25 OH vitamin D level between 10-30 nmol/L.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01170442
Contacts
Contact: Muhammad M Hammami, MD, PhD | 966 1 442 4527 | muhammad@kfshrc.edu.sa |
Locations
Saudi Arabia | |
King Faisal Specialist Hospital & Research Center | Recruiting |
Riyadh, Saudi Arabia, 11211 | |
Contact: Muhammad M Hammami, MD, PhD muhammad@kfshrc.edu.sa |
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: | Muhammad M Hammami, MD, PhD | King Faisal Specialist Hospital & Research Center |
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
Responsible Party: | Muhammad Maher Hammami, Chairman, Department of Clinical Studies & Empirical Ethics, King Faisal Specialist Hospital & Research Center |
ClinicalTrials.gov Identifier: | NCT01170442 History of Changes |
Other Study ID Numbers: | RAC 2101039 |
Study First Received: | July 25, 2010 |
Last Updated: | December 11, 2011 |
Health Authority: | Saudi Arabia: National Committee of Biological and Medical Ethics |
Additional relevant MeSH terms:
Diabetes Mellitus Vitamin D Deficiency Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders |
Cholecalciferol Vitamin D Ergocalciferols Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on October 17, 2012